

## Meeting with the European Social Insurance Platform/ESIP 12/04/2018

**Participants:**

**ESIP:** ██████████ (ESIP President), ██████████ (ESIP Director), ██████████, (ESIP Vice-President), ██████████ (Main Association of Austrian Social Security Institutions, European Representation, Head of Office), ██████████ (Health advisor of the EU Office of the French national social security institutions)

**EC:** Commissioner Vytenis Andriukaitis, Annika Novak (CAB), Nicolas Pradalie (CAB), [REDACTED] (SANTE B5), [REDACTED] (SANTE B4)

The meeting was organised at ESIP's request. The following issues were addressed during the meeting:

- [illegible]

[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]

**4. Incentives for pharmaceutical innovation – follow-up to Council Conclusions June 2016 and Copenhagen Economics Report.**

ESIP asked about the state of play regarding the joint SANTE/GROW study on the impact of Supplementary Protection Certificates and pharmaceutical incentives on innovation, availability and accessibility of medicinal products in the European Union. It was explained that the study is ongoing and should be finalised and published by the summer. It was also stressed that SANTE is evaluating the legislation on medicines for rare diseases and paediatrics, and that the evaluation findings will help to take an informed decision about the way forward regarding legislation on pharmaceuticals for children and rare diseases.

In response to a question on SPC-related activities, it was explained that DG GROW, responsible for this file, is working on the issue of the SPC manufacturing waiver but that currently there is no firm decision to legislate on this aspect. If a legal initiative would be proposed by the summer, the publication of the joint SANTE/GROW study on incentives would be published in the same period of time.

[REDACTED]  
[REDACTED]  
Unit B4 – Medical products: safety, quality, innovation  
[REDACTED]  
[REDACTED]